Arrowhead Pharmaceuticals shares surge 10.28% intraday after FDA grants Breakthrough Therapy designation for plozasiran in severe hypertriglyceridemia.

Arrowhead Pharmaceuticals surged 10.28% intraday after receiving FDA Breakthrough Therapy Designation for plozasiran in treating severe hypertriglyceridemia. This regulatory milestone accelerates development and signals the drug’s potential to significantly reduce triglyceride levels in patients with limited treatment options. The designation, coupled with Phase 3 trials on track for mid-2026, positions the therapy as a promising candidate for approval, bolstering investor confidence. While insider selling and mixed institutional activity were noted, the FDA news overshadowed these factors, driving the sharp intraday rally.